{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:49:24Z","timestamp":1791920964011,"version":"4.3.4"},"reference-count":125,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T00:00:00Z","timestamp":1717459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004836","name":"Independent Research Fund Denmark","doi-asserted-by":"publisher","award":["3188-00020B"],"award-info":[{"award-number":["3188-00020B"]}],"id":[{"id":"10.13039\/501100004836","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Background: Although antiretroviral therapy (ART) effectively halts disease progression in HIV infection, the complete eradication of the virus remains elusive. Additionally, challenges such as long-term ART toxicity, drug resistance, and the demanding regimen of daily and lifelong adherence required by ART highlight the imperative need for alternative therapeutic and preventative approaches. In recent years, broadly neutralizing antibodies (bNAbs) have emerged as promising candidates, offering potential for therapeutic, preventative, and possibly curative interventions against HIV infection. Objective: This review aims to provide a comprehensive overview of the current state of knowledge regarding the passive immunization of bNAbs in HIV-1-infected individuals. Main findings: Recent findings from clinical trials have highlighted the potential of bNAbs in the treatment, prevention, and quest for an HIV-1 cure. While monotherapy with a single bNAb is insufficient in maintaining viral suppression and preventing viral escape, ultimately leading to viral rebound, combination therapy with potent, non-overlapping epitope-targeting bNAbs have demonstrated prolonged viral suppression and delayed time to rebound by effectively restricting the emergence of escape mutations, albeit largely in individuals with bNAb-sensitive strains. Additionally, passive immunization with bNAb has provided a \u201cproof of concept\u201d for antibody-mediated prevention against HIV-1 acquisition, although complete prevention has not been obtained. Therefore, further research on the use of bNAbs in HIV-1 treatment and prevention remains imperative.<\/jats:p>","DOI":"10.3390\/v16060911","type":"journal-article","created":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T08:43:54Z","timestamp":1717577034000},"page":"911","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["The Use of Broadly Neutralizing Antibodies (bNAbs) in HIV-1 Treatment and Prevention"],"prefix":"10.3390","volume":"16","author":[{"given":"Jannifer Jasmin","family":"Thavarajah","sequence":"first","affiliation":[{"name":"Faculty of Health, Aarhus University, 8000 Aarhus C, Denmark"},{"name":"Clinical Medicine, Department of Infectious Diseases, Aarhus University Hospital, 8200 Aarhus N, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo Langhoff","family":"H\u00f8nge","sequence":"additional","affiliation":[{"name":"Clinical Medicine, Department of Infectious Diseases, Aarhus University Hospital, 8200 Aarhus N, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2534-2942","authenticated-orcid":false,"given":"Christian Morberg","family":"Wejse","sequence":"additional","affiliation":[{"name":"Clinical Medicine, Department of Infectious Diseases, Aarhus University Hospital, 8200 Aarhus N, Denmark"},{"name":"GloHAU, Center of Global Health, Department of Public Health, Aarhus University, 8000 Aarhus C, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,6,4]]},"reference":[{"key":"ref_1","unstructured":"UNAIDS (2023). Global HIV & AIDS Statistics\u2014Fact Sheet, UNAIDS Secretariat 20."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"413","DOI":"10.3201\/eid2403.171797","article-title":"Ending the HIV\/AIDS Pandemic(1)","volume":"24","author":"Eisinger","year":"2018","journal-title":"Emerg. Infect. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ijid.2018.10.011","article-title":"Non-AIDS-related comorbidities in people living with HIV-1 aged 50 years and older: The AGING POSITIVE study","volume":"79","author":"Velez","year":"2019","journal-title":"Int. J. Infect. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2147\/HIV.S129992","article-title":"The social stigma of HIV-AIDS: Society\u2019s role","volume":"9","author":"Kontomanolis","year":"2017","journal-title":"HIV AIDS Res. Palliat. Care"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s40121-018-0201-6","article-title":"A Review of Long-Term Toxicity of Antiretroviral Treatment Regimens and Implications for an Aging Population","volume":"7","author":"Chawla","year":"2018","journal-title":"Infect. Dis. Ther."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.4081\/idr.2013.s1.e5","article-title":"HIV Drug Resistance: Problems and Perspectives","volume":"5","author":"Pennings","year":"2013","journal-title":"Infect. Dis. Rep."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/nature11604","article-title":"HIV therapy by a combination of broadly neutralizing antibodies in humanized mice","volume":"492","author":"Klein","year":"2012","journal-title":"Nature"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/nature12746","article-title":"Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia","volume":"503","author":"Shingai","year":"2013","journal-title":"Nature"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/nature12744","article-title":"Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys","volume":"503","author":"Barouch","year":"2013","journal-title":"Nature"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.mayocp.2015.03.008","article-title":"Can HIV Be Cured and Should We Try?","volume":"90","author":"Cummins","year":"2015","journal-title":"Mayo Clin. Proc."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Yeo, J.Y., Goh, G.R., Su, C.T., and Gan, S.K. (2020). The Determination of HIV-1 RT Mutation Rate, Its Possible Allosteric Effects, and Its Implications on Drug Resistance. Viruses, 12.","DOI":"10.20944\/preprints202002.0099.v1"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1126\/science.7824947","article-title":"HIV population dynamics in vivo: Implications for genetic variation, pathogenesis, and therapy","volume":"267","author":"Coffin","year":"1995","journal-title":"Science"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Jin, X., Wang, Z., Zhang, Z., Wu, H., Ruan, Y., Zhang, C., Kang, R., Xing, H., and Lou, J. (2021). The transmission of drug-resistant strains of HIV in heterosexual populations based on genetic sequences. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0259023"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Mokgethi, P.T., Choga, W.T., Maruapula, D., Moraka, N.O., Seatla, K.K., Bareng, O.T., Ditshwanelo, D.D., Mulenga, G., Mohammed, T., and Kaumba, P.M. (2024). High prevalence of pre-treatment and acquired HIV-1 drug resistance mutations among non-citizens living with HIV in Botswana. Front. Microbiol., 15.","DOI":"10.3389\/fmicb.2024.1338191"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/nature04817","article-title":"Distribution and three-dimensional structure of AIDS virus envelope spikes","volume":"441","author":"Zhu","year":"2006","journal-title":"Nature"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1146\/annurev-immunol-041015-055515","article-title":"Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design","volume":"34","author":"Burton","year":"2016","journal-title":"Annu. Rev. Immunol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"105788","DOI":"10.1016\/j.antiviral.2023.105788","article-title":"Next-generation bNAbs for HIV-1 cure strategies","volume":"222","author":"Schriek","year":"2024","journal-title":"Antivir. Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.coph.2019.03.003","article-title":"Phylogenies in ART: HIV reservoirs, HIV latency and drug resistance","volume":"48","author":"Bandera","year":"2019","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"718763","DOI":"10.3389\/fphar.2021.718763","article-title":"Transmitted Drug Resistance in Antiretroviral Therapy-Naive Persons With Acute\/Early\/Primary HIV Infection: A Systematic Review and Meta-Analysis","volume":"12","author":"Guo","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"167","DOI":"10.2174\/187152611795589663","article-title":"HIV treatment adherence, drug resistance, virologic failure: Evolving concepts","volume":"11","author":"Nachega","year":"2011","journal-title":"Infect. Disord. Drug Targets"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1126\/science.1241144","article-title":"Antibodies in HIV-1 vaccine development and therapy","volume":"341","author":"Klein","year":"2013","journal-title":"Science"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e25829","DOI":"10.1002\/jia2.25829","article-title":"Broadly neutralizing monoclonal antibodies for HIV prevention","volume":"24","author":"Miner","year":"2021","journal-title":"J. Int. AIDS Soc."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.tibs.2014.12.006","article-title":"Insights into the trimeric HIV-1 envelope glycoprotein structure","volume":"40","author":"Ward","year":"2015","journal-title":"Trends Biochem. Sci."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nature01470","article-title":"Antibody neutralization and escape by HIV-1","volume":"422","author":"Wei","year":"2003","journal-title":"Nature"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"7252","DOI":"10.1021\/acsomega.2c07933","article-title":"An Overview of Human Anti-HIV-1 Neutralizing Antibodies against Diverse Epitopes of HIV-1","volume":"8","author":"Kumar","year":"2023","journal-title":"ACS Omega"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/nature10373","article-title":"Broad neutralization coverage of HIV by multiple highly potent antibodies","volume":"477","author":"Walker","year":"2011","journal-title":"Nature"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/s41591-019-0412-8","article-title":"Broadly neutralizing anti-HIV-1 monoclonal antibodies in the clinic","volume":"25","author":"Caskey","year":"2019","journal-title":"Nat. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"109809","DOI":"10.1016\/j.clim.2023.109809","article-title":"Broadly neutralizing antibodies targeting HIV: Progress and challenges","volume":"257","author":"Paneerselvam","year":"2023","journal-title":"Clin. Immunol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.molimm.2015.03.255","article-title":"Molecular properties of human IgG subclasses and their implications for designing therapeutic monoclonal antibodies against infectious diseases","volume":"67","author":"Irani","year":"2015","journal-title":"Mol. Immunol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"10844","DOI":"10.1038\/ncomms10844","article-title":"Elimination of HIV-1-infected cells by broadly neutralizing antibodies","volume":"7","author":"Bruel","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1126\/science.1178746","article-title":"Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target","volume":"326","author":"Walker","year":"2009","journal-title":"Science"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1128\/JVI.80.5.2515-2528.2006","article-title":"Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1","volume":"80","author":"Moore","year":"2006","journal-title":"J. Virol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1126\/science.1213256","article-title":"A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield","volume":"334","author":"Pejchal","year":"2011","journal-title":"Science"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/nature05115","article-title":"PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression","volume":"443","author":"Day","year":"2006","journal-title":"Nature"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/j.1365-2249.2009.03960.x","article-title":"Programmed death (PD)-1 molecule and its ligand PD-L1 distribution among memory CD4 and CD8 T cell subsets in human immunodeficiency virus-1-infected individuals","volume":"157","author":"Rosignoli","year":"2009","journal-title":"Clin. Exp. Immunol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/COH.0000000000000154","article-title":"History of passive antibody administration for prevention and treatment of infectious diseases","volume":"10","author":"Graham","year":"2015","journal-title":"Curr. Opin. HIV AIDS"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1128\/CMR.13.4.602","article-title":"Passive immunity in prevention and treatment of infectious diseases","volume":"13","author":"Keller","year":"2000","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Delgado, M., and Garcia-Sanz, J.A. (2023). Therapeutic Monoclonal Antibodies against Cancer: Present and Future. Cells, 12.","DOI":"10.3390\/cells12242837"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.coph.2018.05.010","article-title":"Monoclonal antibodies as immunomodulatory therapy against cancer and autoimmune diseases","volume":"41","author":"Hafeez","year":"2018","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"4009","DOI":"10.1128\/JVI.73.5.4009-4018.1999","article-title":"Protection of Macaques against pathogenic simian\/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies","volume":"73","author":"Mascola","year":"1999","journal-title":"J. Virol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/5568","article-title":"Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1\/SIV chimeric virus infections of macaque monkeys","volume":"5","author":"Shibata","year":"1999","journal-title":"Nat. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/72309","article-title":"Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection","volume":"6","author":"Baba","year":"2000","journal-title":"Nat. Med."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Hessell, A.J., Rakasz, E.G., Poignard, P., Hangartner, L., Landucci, G., Forthal, D.N., Koff, W.C., Watkins, D.I., and Burton, D.R. (2009). Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog., 5.","DOI":"10.1371\/journal.ppat.1000433"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1097\/00002030-200210180-00006","article-title":"Antiviral activity of the neutralizing antibodies 2F5 and 2G12 in asymptomatic HIV-1-infected humans: A phase I evaluation","volume":"16","author":"Stiegler","year":"2002","journal-title":"Aids"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/00002030-200201250-00012","article-title":"A phase I trial with two human monoclonal antibodies (hMAb 2F5, 2G12) against HIV-1","volume":"16","author":"Armbruster","year":"2002","journal-title":"AIDS"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1093\/jac\/dkh428","article-title":"Passive immunization with the anti-HIV-1 human monoclonal antibody (hMAb) 4E10 and the hMAb combination 4E10\/2F5\/2G12","volume":"54","author":"Armbruster","year":"2004","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1128\/AAC.50.5.1773-1779.2006","article-title":"Long-term multiple-dose pharmacokinetics of human monoclonal antibodies (MAbs) against human immunodeficiency virus type 1 envelope gp120 (MAb 2G12) and gp41 (MAbs 4E10 and 2F5)","volume":"50","author":"Joos","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/nm1244","article-title":"Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies","volume":"11","author":"Trkola","year":"2005","journal-title":"Nat. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"11016","DOI":"10.1128\/JVI.01340-07","article-title":"Adjunctive passive immunotherapy in human immunodeficiency virus type 1-infected individuals treated with antiviral therapy during acute and early infection","volume":"81","author":"Mehandru","year":"2007","journal-title":"J. Virol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"14039","DOI":"10.1128\/JVI.78.24.14039-14042.2004","article-title":"Neutralization profiles of newly transmitted human immunodeficiency virus type 1 by monoclonal antibodies 2G12, 2F5, and 4E10","volume":"78","author":"Mehandru","year":"2004","journal-title":"J. Virol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1126\/science.1111781","article-title":"Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies","volume":"308","author":"Haynes","year":"2005","journal-title":"Science"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1084\/jem.20121977","article-title":"Identification of autoantigens recognized by the 2F5 and 4E10 broadly neutralizing HIV-1 antibodies","volume":"210","author":"Yang","year":"2013","journal-title":"J. Exp. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1089\/aid.1998.14.545","article-title":"Phase I study of a human monoclonal antibody directed against the CD4-binding site of HIV type 1 glycoprotein 120","volume":"14","author":"Cavacini","year":"1998","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/COH.0000000000000802","article-title":"Broadly neutralizing antibodies for HIV treatment and cure approaches","volume":"18","author":"Frattari","year":"2023","journal-title":"Curr. Opin. HIV AIDS"},{"key":"ref_55","unstructured":"Widge, A.T. (2020, January 8\u201311). A phase i dose-escalation trial of human monoclonal antibody n6ls in healthy adults. Proceedings of the Conference on Retroviruses and Opportunistic Infections (Croi), Boston, MA, USA."},{"key":"ref_56","unstructured":"A Study to Evaluate the Antiviral Effect, Safety and Tolerability of GSK3810109A in Viremic Human Immunodeficiency Virus (HIV)-1 Infected Adults (Standard No. NCT04871113). Available online: https:\/\/ichgcp.net\/clinical-trials-registry\/NCT04871113."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/cei.12692","article-title":"Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults","volume":"182","author":"Ledgerwood","year":"2015","journal-title":"Clin. Exp. Immunol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"319ra206","DOI":"10.1126\/scitranslmed.aad5752","article-title":"Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection","volume":"7","author":"Lynch","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1056\/NEJMoa1608243","article-title":"Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption","volume":"375","author":"Bar","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Mayer, K.H., Seaton, K.E., Huang, Y., Grunenberg, N., Isaacs, A., Allen, M., Ledgerwood, J.E., Frank, I., Sobieszczyk, M.E., and Baden, L.R. (2017). Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial. PLoS Med., 14.","DOI":"10.1371\/journal.pmed.1002435"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"ofy242","DOI":"10.1093\/ofid\/ofy242","article-title":"Randomized Clinical Trial to Assess the Impact of the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01 on HIV-1 Persistence in Individuals on Effective ART","volume":"5","author":"Riddler","year":"2018","journal-title":"Open Forum Infect. Dis."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"e297","DOI":"10.1016\/S2352-3018(19)30053-0","article-title":"Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): A phase 2, randomised, double-blind, placebo-controlled trial","volume":"6","author":"Crowell","year":"2019","journal-title":"Lancet HIV"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Gaudinski, M.R., Coates, E.E., Houser, K.V., Chen, G.L., Yamshchikov, G., Saunders, J.G., Holman, L.A., Gordon, I., Plummer, S., and Hendel, C.S. (2018). Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults. PLoS Med., 15.","DOI":"10.1371\/journal.pmed.1002493"},{"key":"ref_64","unstructured":"Gaudinski, M.R. (2021, February 23). Safety and Virologic Effect of the HIV-1 Broadly Neutralizing Antibodies, VRC01LS or VRC07-523LS, Administered to HIV-Infected Adults in a Phase 1 Clinical Trial, Available online: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT02840474."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"e667","DOI":"10.1016\/S2352-3018(19)30181-X","article-title":"Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: A phase 1 dose-escalation clinical trial","volume":"6","author":"Gaudinski","year":"2019","journal-title":"Lancet HIV"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/nature14411","article-title":"Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117","volume":"522","author":"Caskey","year":"2015","journal-title":"Nature"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/nature18929","article-title":"HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption","volume":"535","author":"Scheid","year":"2016","journal-title":"Nature"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1084\/jem.20180936","article-title":"Relationship between latent and rebound viruses in a clinical trial of anti-HIV-1 antibody 3BNC117","volume":"215","author":"Cohen","year":"2018","journal-title":"J. Exp. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nm.4268","article-title":"Antibody 10-1074 suppresses viremia in HIV-1-infected individuals","volume":"23","author":"Caskey","year":"2017","journal-title":"Nat. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1038\/s41591-021-01509-0","article-title":"Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: A randomized, placebo-controlled, phase 1 clinical trial","volume":"27","author":"Stephenson","year":"2021","journal-title":"Nat. Med."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Cohen, Y.Z., Butler, A.L., Millard, K., Witmer-Pack, M., Levin, R., Unson-O\u2019Brien, C., Patel, R., Shimeliovich, I., Lorenzi, J.C.C., and Horowitz, J. (2019). Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10-1074 in healthy adults: A randomized, phase 1 study. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0219142"},{"key":"ref_72","unstructured":"Andriesen, J. (2019). Evaluating the Safety, Pharmacokinetics, and Anti-Viral Activity of VRC01 and VRC01LS in the Serum and Mucosa of Healthy, HIV-Uninfected Adults, Fred Hutchinson Cancer Research Center."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.1172\/JCI134395","article-title":"Neutralizing antibody VRC01 failed to select for HIV-1 mutations upon viral rebound","volume":"130","author":"Cale","year":"2020","journal-title":"J. Clin. Investig."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1056\/NEJMoa2031738","article-title":"Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition","volume":"384","author":"Corey","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1126\/science.aaf0972","article-title":"HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1","volume":"352","author":"Schoofs","year":"2016","journal-title":"Science"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1802264","article-title":"Effect of Anti-CD4 Antibody UB-421 on HIV-1 Rebound after Treatment Interruption","volume":"380","author":"Wang","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1038\/s41591-018-0186-4","article-title":"Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals","volume":"24","author":"Gruell","year":"2018","journal-title":"Nat. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1038\/s41591-022-01815-1","article-title":"Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: A phase 1 clinical trial","volume":"28","author":"Julg","year":"2022","journal-title":"Nat. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/s41586-018-0531-2","article-title":"Combination therapy with anti-HIV-1 antibodies maintains viral suppression","volume":"561","author":"Mendoza","year":"2018","journal-title":"Nature"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/s41586-022-04597-1","article-title":"Prolonged viral suppression with anti-HIV-1 antibody therapy","volume":"606","author":"Gaebler","year":"2022","journal-title":"Nature"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/s41586-022-04797-9","article-title":"Combination anti-HIV antibodies provide sustained virological suppression","volume":"606","author":"Sneller","year":"2022","journal-title":"Nature"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"e653","DOI":"10.1016\/S2352-3018(23)00140-6","article-title":"Safety, tolerability, pharmacokinetics, and immunological activity of dual-combinations and triple-combinations of anti-HIV monoclonal antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS administered intravenously to HIV-uninfected adults: A phase 1 randomised trial","volume":"10","author":"Sobieszczyk","year":"2023","journal-title":"Lancet HIV"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1093\/infdis\/jiac041","article-title":"Safety and Pharmacokinetics of Monoclonal Antibodies VRC07-523LS and PGT121 Administered Subcutaneously for Human Immunodeficiency Virus Prevention","volume":"226","author":"Mahomed","year":"2022","journal-title":"J. Infect. Dis."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"e230","DOI":"10.1016\/S2352-3018(23)00003-6","article-title":"Safety and pharmacokinetics of escalating doses of neutralising monoclonal antibody CAP256V2LS administered with and without VRC07-523LS in HIV-negative women in South Africa (CAPRISA 012B): A phase 1, dose-escalation, randomised controlled trial","volume":"10","author":"Mahomed","year":"2023","journal-title":"Lancet HIV"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"175375","DOI":"10.1172\/jci.insight.175375","article-title":"Phase 1 trial evaluating safety and pharmacokinetics of HIV-1 broadly neutralizing mAbs 10E8VLS and VRC07-523LS","volume":"9","author":"Awan","year":"2024","journal-title":"JCI Insight"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/s41591-019-0747-1","article-title":"Combination anti-HIV-1 antibody therapy is associated with increased virus-specific T cell immunity","volume":"26","author":"Niessl","year":"2020","journal-title":"Nat. Med."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"4781","DOI":"10.1182\/blood-2005-12-4818","article-title":"HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells","volume":"107","author":"Betts","year":"2006","journal-title":"Blood"},{"key":"ref_88","unstructured":"WHO (2022). WHO Preferred Product Characteristics for Monoclonal Antibodies for HIV Prevention, WHO."},{"key":"ref_89","unstructured":"Clinicaltrials.gov (2024, March 23). Phase II Trial of ART + Dual bNAbs vs. ART + Placebo During Primary HIV-1 Infection-impact on Post-ART Control (RHIVIERA-02), Available online: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05300035."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41586-018-0600-6","article-title":"Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys","volume":"563","author":"Borducchi","year":"2018","journal-title":"Nature"},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Moldt, B., Chandrashekar, A., Borducchi, E.N., Nkolola, J.P., Stephenson, H., Nagel, M., Hung, M., Goldsmith, J., Pace, C.S., and Carr, B. (2022). HIV envelope antibodies and TLR7 agonist partially prevent viral rebound in chronically SHIV-infected monkeys. PLoS Pathog., 18.","DOI":"10.1371\/journal.ppat.1010467"},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Hsu, D.C., Schuetz, A., Imerbsin, R., Silsorn, D., Pegu, A., Inthawong, D., Sopanaporn, J., Visudhiphan, P., Chuenarom, W., and Keawboon, B. (2021). TLR7 agonist, N6-LS and PGT121 delayed viral rebound in SHIV-infected macaques after antiretroviral therapy interruption. PLoS Pathog., 17.","DOI":"10.1371\/journal.ppat.1009339"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"e203","DOI":"10.1016\/S2666-5247(21)00239-1","article-title":"Effect of 3BNC117 and romidepsin on the HIV-1 reservoir in people taking suppressive antiretroviral therapy (ROADMAP): A randomised, open-label, phase 2A trial","volume":"3","author":"Gruell","year":"2022","journal-title":"Lancet Microbe"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1093\/infdis\/jiab487","article-title":"Stable Latent HIV Infection and Low-level Viremia Despite Treatment With the Broadly Neutralizing Antibody VRC07-523LS and the Latency Reversal Agent Vorinostat","volume":"225","author":"Gay","year":"2022","journal-title":"J. Infect. Dis."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1038\/s41591-022-02023-7","article-title":"Early intervention with 3BNC117 and romidepsin at antiretroviral treatment initiation in people with HIV-1: A phase 1b\/2a, randomized trial","volume":"28","author":"Gunst","year":"2022","journal-title":"Nat. Med."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1038\/s41591-023-02547-6","article-title":"Impact of a TLR9 agonist and broadly neutralizing antibodies on HIV-1 persistence: The randomized phase 2a TITAN trial","volume":"29","author":"Gunst","year":"2023","journal-title":"Nat. Med."},{"key":"ref_97","unstructured":"Tebas, P. (2022, January 12\u201316). BEAT2: Peg-INF-a2b + 3BNC117 and 10-1074 keeps HIV at <20 c\/\u03bcL during a 26-week ATI. Proceedings of the CROI Conference 2022 (Poster), Virtual."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Mayer, B., Zhang, L., deCamp, A., Yu, C., Sato, A., Angier, H., Seaton, K., Yates, N., Ledgerwood, J., and Mayer, K. (2024). Impact of LS Mutation on Pharmacokinetics of Preventive HIV Broadly Neutralizing Monoclonal Antibodies: A Cross-Protocol Analysis of 16 Clinical Trials in People without HIV. Pharmaceutics, 16.","DOI":"10.3390\/pharmaceutics16050594"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nature13612","article-title":"Enhanced neonatal Fc receptor function improves protection against primate SHIV infection","volume":"514","author":"Ko","year":"2014","journal-title":"Nature"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"e222","DOI":"10.1016\/S2352-3018(23)00301-6","article-title":"Acceptability and tolerability of long-acting injectable cabotegravir or rilpivirine in the first cohort of virologically suppressed adolescents living with HIV (IMPAACT 2017\/MOCHA): A secondary analysis of a phase 1\/2, multicentre, open-label, non-comparative dose-finding study","volume":"11","author":"Lowenthal","year":"2024","journal-title":"Lancet HIV"},{"key":"ref_101","unstructured":"Caskey, M., Millard, K., and Turroja, M. (2022, January 12\u201316). Phase I study of long-acting 3bnc117 and 10-1074 in viremic adults living with hiv. Proceedings of the Conference on Retroviruses and Opportunistic Infections, Virtual."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/imr.12076","article-title":"HIV controllers: A genetically determined or inducible phenotype?","volume":"254","author":"Pancino","year":"2013","journal-title":"Immunol. Rev."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1038\/s41598-020-58696-y","article-title":"Permanent control of HIV-1 pathogenesis in exceptional elite controllers: A model of spontaneous cure","volume":"10","author":"Casado","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Auvert, B., Taljaard, D., Lagarde, E., Sobngwi-Tambekou, J., Sitta, R., and Puren, A. (2005). Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: The ANRS 1265 Trial. PLoS Med., 2.","DOI":"10.1371\/journal.pmed.0020298"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1097\/QAI.0b013e31823554d7","article-title":"Efficacy of behavioral interventions to increase condom use and reduce sexually transmitted infections: A meta-analysis, 1991 to 2010","volume":"58","author":"Warren","year":"2011","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"E1350","DOI":"10.1503\/cmaj.180311","article-title":"Risk of sexual transmission of human immunodeficiency virus with antiretroviral therapy, suppressed viral load and condom use: A systematic review","volume":"190","author":"LeMessurier","year":"2018","journal-title":"Cmaj"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"e048478","DOI":"10.1136\/bmjopen-2020-048478","article-title":"Oral pre-exposure prophylaxis (PrEP) to prevent HIV: A systematic review and meta-analysis of clinical effectiveness, safety, adherence and risk compensation in all populations","volume":"12","author":"Murchu","year":"2022","journal-title":"BMJ Open"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s15010-015-0850-2","article-title":"HIV pre-exposure prophylaxis (PrEP): A review of current knowledge of oral systemic HIV PrEP in humans","volume":"44","author":"Spinner","year":"2016","journal-title":"Infection"},{"key":"ref_109","unstructured":"UNAIDS (2019). Barriers to PrEP must be Removed, UNAIDS."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1128\/JVI.01272-09","article-title":"Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L","volume":"84","author":"Hessell","year":"2010","journal-title":"J. Virol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/nature17677","article-title":"A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges","volume":"533","author":"Gautam","year":"2016","journal-title":"Nature"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1146\/annurev-immunol-080219-023629","article-title":"Vaccines and Broadly Neutralizing Antibodies for HIV-1 Prevention","volume":"38","author":"Stephenson","year":"2020","journal-title":"Annu. Rev. Immunol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"101470","DOI":"10.1016\/j.smim.2021.101470","article-title":"HIV vaccinology: 2021 update","volume":"51","author":"Lee","year":"2021","journal-title":"Semin. Immunol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1097\/QAD.0000000000003881","article-title":"Impact of antiretroviral therapy during acute or early HIV infection on virologic and immunologic outcomes: Results from a multinational clinical trial","volume":"38","author":"Crowell","year":"2024","journal-title":"Aids"},{"key":"ref_115","unstructured":"Partners In Health (2024, March 04). \u2018A Moral Failure\u2019: Global Vaccine Inequity Hits Africa Hardest. Available online: https:\/\/www.pih.org\/article\/moral-failure-global-vaccine-inequity-hits-africa-hardest."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s41182-023-00564-2","article-title":"Vaccine inequity: A threat to Africa\u2019s recovery from COVID-19","volume":"51","author":"Wei","year":"2023","journal-title":"Trop. Med. Health"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/s41591-022-01762-x","article-title":"Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: A phase 1, dose-escalation trial","volume":"28","author":"Casazza","year":"2022","journal-title":"Nat. Med."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"e230","DOI":"10.1016\/S2352-3018(19)30003-7","article-title":"Adeno-associated virus vectored immunoprophylaxis to prevent HIV in healthy adults: A phase 1 randomised controlled trial","volume":"6","author":"Priddy","year":"2019","journal-title":"Lancet HIV"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1016\/j.cell.2016.05.024","article-title":"Engineered Bispecific Antibodies with Exquisite HIV-1-Neutralizing Activity","volume":"165","author":"Huang","year":"2016","journal-title":"Cell"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1126\/science.aan8630","article-title":"Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques","volume":"358","author":"Xu","year":"2017","journal-title":"Science"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/s41467-018-03335-4","article-title":"Rational design of a trispecific antibody targeting the HIV-1 Env with elevated anti-viral activity","volume":"9","author":"Steinhardt","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12977-019-0493-y","article-title":"Engineering and characterising a novel, highly potent bispecific antibody iMab-CAP256 that targets HIV-1","volume":"16","author":"Moshoette","year":"2019","journal-title":"Retrovirology"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.3389\/fimmu.2020.01951","article-title":"The Molecular Mechanisms That Underlie the Immune Biology of Anti-drug Antibody Formation Following Treatment With Monoclonal Antibodies","volume":"11","author":"DeKosky","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.meegid.2016.08.010","article-title":"Hiv-2 molecular epidemiology","volume":"46","author":"Visseaux","year":"2016","journal-title":"Infect. Genet. Evol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s12981-019-0239-x","article-title":"HIV-2 as a model to identify a functional HIV cure","volume":"16","author":"Jansson","year":"2019","journal-title":"AIDS Res. Ther."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/16\/6\/911\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:53:21Z","timestamp":1760108001000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/16\/6\/911"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,4]]},"references-count":125,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,6]]}},"alternative-id":["v16060911"],"URL":"https:\/\/doi.org\/10.3390\/v16060911","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,4]]}}}